Cell Therapy News Volume 19.36 | Oct 29 2018

TOP STORY

Lin⁻CCR2⁺ Hematopoietic Stem and Progenitor Cells Overcome Resistance to PD-1 Blockade

In CNS malignancies that were completely resistant to PD-1 blockade, scientists found that bone marrow-derived, lineage-negative hematopoietic stem and progenitor cells that express C-C chemokine receptor type 2 (CCR2⁺) reversed treatment resistance and sensitized mice to curative immunotherapy. [Nat Commun] Full Article

(Ranked by impact factor of the journal)

Clearance of Treatment-Refractory Adenoviremia via Adenovirus-Specific Donor T-Cell Transfer during Aplasia after αβTCR-CD19-Depleted Stem Cell Transplantation

Researchers report the case of severe adenoviremia in a seven-year-old boy with highly resistant acute leukaemia. A combined approach of TCR-CD19-depleted stem cell transplantation enabling immunosuppression-free post transplant care and early transfer of ADV-specific donor T cells during aplasia resulted in rapid and complete clearance of the treatment-refractory adenoviremia. [Clin Infect Dis] Abstract

Worm-Like Biomimetic Nanoerythrocyte Carrying siRNA for Melanoma Gene Therapy

Due to outstanding biocompatibility and active targeting, the 7 mg kg⁻¹ dose siSurvivin in RGD-red blood cell-reversible polyplex exhibited obviously superior anticancer effects at the animal level after two weeks. [Small] Abstract

Connexin 43-Mediated Mitochondrial Transfer of iPSC-MSCs Alleviates Asthma Inflammation

Investigators found that induced pluripotent stem cell-derived mesenchymal stem cells (iPSC-MSCs) transplantation significantly reduced T helper 2 cytokines, attenuated the mitochondrial dysfunction of epithelial cells, and alleviated asthma inflammation in mice. [Stem Cell Reports] Full Article | Graphical Abstract

CRISPR/Cas9-Mediated Disruption of SHANK3 in Monkey Leads to Drug-Treatable Autism-Like Symptoms

Scientists used CRISPR/Cas9 to generate a cynomolgus monkey model by disrupting SHANK3 at exon 6 and 12. Analysis of the live mutant monkey revealed the core behavioral abnormalities of autism spectrum disorder, including impaired social interaction and repetitive behaviors, and reduced brain network activities detected by positron-emission tomography. [Hum Mol Genet] Abstract

Cardiac Mesenchymal Cells from Diabetic Mice Are Ineffective for Cell Therapy-Mediated Myocardial Repair

To test whether metabolic improvement of cardiac mesenchymal cells from diabetic B6.BKS(D)-Leprdb/J (CMC^db/db) cells renders them suitable for cell therapy, scientists cultured CMCs from non-diabetic C57BL/6J or CMCdb/db cells in 5.5 mM glucose and then injected them into infarcted hearts of non-diabetic mice. [Basic Res Cardiol] Abstract

3D-Cultured Human Placenta-Derived Mesenchymal Stem Cell Spheroids Enhance Ovary Function by Inducing Folliculogenesis

The authors demonstrated the therapeutic effect of placenta-derived mesenchymal stem cells in ovariectomized rats and compared their efficacy when generated via a conventional monolayer culture system and a spheroid culture system. [Sci Rep] Full Article

Tissue Engineering the Human Auricle by Auricular Chondrocyte-Mesenchymal Stem Cell Co-Implantation

Investigators present a full-scale, patient-based human ear generated by implantation of human auricular chondrocytes and human mesenchymal stem cells in a 1:1 ratio. [PLoS One] Full Article

Intratracheal Transplantation of Mesenchymal Stem Cells Attenuates Hyperoxia-Induced Lung Injury by Down-Regulating, but Not Direct Inhibiting Formyl Peptide Receptor 1 in the Newborn Mice

The authors investigated whether formyl peptide receptor 1 (FPR1) plays a pivotal role in regulating lung inflammation and injuries, and whether intratracheally transplanted mesenchymal stem cells attenuate hyperoxic lung inflammation and injuries by down-regulating FPR1. [PLoS One] Full Article

Transplantation, Gene Therapy and Intestinal Pathology in MNGIE Patients and Mice

Researchers evaluated the intestinal neuromuscular pathology in a mouse model of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) treated with hematopoietic stem cell gene therapy. [BMC Gastroenterol] Full Article

Subscribe to one of our other 19 science newsletters such as Mesenchymal Cell News & ESC & iPSC News.

Corneal Cell Therapy: With iPSCs, It Is No More a Far-Sight

The authors discuss and summarize protocols that have been devised so far to direct differentiation of human pluripotent stem cells to different corneal cell phenotypes. [Stem Cell Res Ther] Full Article

Visit our reviews page to see a complete list of reviews in the cell therapy research field.

STEMCELL Submits Drug Master File for mTeSR™1, the Most Widely Published Cell Culture Medium for Human Pluripotent Stem Cells

STEMCELL Technologies announced it has filed a Type II Drug Master File (DMF) to the FDA for the Cellular Therapy Ancillary Material mTeSR™1 and has been issued DMF# 18339. [STEMCELL Technologies Inc.] Press Release

The Parker Institute for Cancer Immunotherapy Partners with Xyphos Biosciences to Develop Universal Programmable CAR-T Cells for Cancer Treatment

The Parker Institute for Cancer Immunotherapy and Xyphos Biosciences announced a collaboration to create universal CAR-T therapies to treat multiple cancer types using the company’s ‘convertibleCAR’^® platform. [The Parker Institute for Cancer Immunotherapy] Press Release

Lilly and Dicerna Announce RNAi Licensing and Research Collaboration

Eli Lilly and Company and Dicerna Pharmaceuticals announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain. [Eli Lilly and Company] Press Release

Axovant Announces Dosing of First Patient in Clinical Study of AXO-Lenti-PD, a Novel Gene Therapy for Patients with Parkinson’s Disease

Axovant Sciences announced dosing of the first patient in a clinical study of AXO-Lenti-PD, an investigational gene therapy for the treatment of Parkinson’s disease. [Axovant Sciences, Inc.] Press Release

Fibrocell Receives Guidance from FDA on Phase III Clinical Trial Design for FCX-007

Fibrocell Science, Inc. announced completion of a Type C meeting with the FDA to discuss the design of a Phase III clinical trial protocol of FCX-007, the company’s gene therapy candidate for the treatment of recessive dystrophic epidermolysis bullosa. [Fibrocell Science, Inc.] Press Release

AIVITA Biomedical Enrolls First Patient in Phase II Glioblastoma Trial

AIVITA Biomedical, Inc. announced the enrollment of its first patient in the company’s Phase II clinical trial for newly diagnosed glioblastoma. [AIVITA Biomedical, Inc.] Press Release

SpinalCyte Announces Positive 12 Month Pain Data from Phase I/Phase II Clinical Trial for Degenerative Disc Disease

SpinalCyte, LLC announced 12-month endpoint data from its Phase I/Phase II clinical trial for treatment of degenerative disc disease. [SpinalCyte, LLC] Press Release

‘Tropical Trump’ Victory in Brazil Stuns Scientists

Former military officer Jair Bolsonaro rode a wave of anti-establishment anger to victory in Brazil’s presidential election on 28 October, leaving many researchers stunned and worried about the future of their country. [Nature News] Editorial

Embattled University Switches Countries in the Face of Controversial Law

An international university in Budapest that has been at the centre of a struggle between Hungarian liberals and the country’s right-wing government has decided to transfer its next batch of master’s and doctoral students to Austria. [Nature News] Editorial

What a Massive Database of Retracted Papers Reveals about Science Publishing’s ‘Death Penalty’

Nearly a decade ago, headlines highlighted a disturbing trend in science: The number of articles retracted by journals had increased 10-fold during the previous 10 years. Fraud accounted for some 60% of those retractions; one offender, anesthesiologist Joachim Boldt, had racked up almost 90 retractions after investigators concluded he had fabricated data and committed other ethical violations. [ScienceInsider] Editorial

NIH

Proposed Collection; 60-Day Comment Request; Investigational Agent Accountability Record Forms in the Conduct of Investigational Trials for the Treatment of Cancer (National Cancer Institute) (FR Doc. No:2018-23313) Notice

NEW 60^th American Society of Hematology (ASH) Annual Meeting & Exposition
December 1-4, 2018
San Diego, California, United States

Visit our events page to see a complete list of events in the community.

NEW Executive Director – Cell and Gene Medicine (Stanford University)

Faculty Positions – Hematology and Oncology (University of California Davis)

PhD and Posdoctoral Research Positions – Innate Immunity (Universitatsklinikum Tubingen)

Lab Technologist – Cell Therapy (University of Maryland Medical Center)

Quality Control Scientists/Analysts – Cell and Gene Therapy (GlaxoSmithKline)

Postdoctoral Fellow – Stem Cell Biology/Stroke, and Alzheimer’s Disease Research (Tulane University)

Open Rank Professor – Biopharmaceutical Discovery (University of Delaware)

Assistant Professor – Biology (University of Delaware)

Research Associate – Immunotherapy (Baylor College of Medicine)

Postdoctoral Position – Cancer, Immunology, and/or Single-Cell Epigenomics (CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences)

Director – Clinical Development (California Institute for Biomedical Research)

Faculty Position – Adoptive T Cell Therapy (Dana-Farber Cancer Institute)

Professorship – Somatic Gene Therapy (University of Zurich)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cell Therapy News? Click here to submit!

Comments or suggestions? Submit your feedback here.